CMTM6 expression has previously been demonstrated as a promising biomarker that is useful for PD-1/PD-L1 inhibitor therapeutic decision-making in non-small-cell lung cancer [4, 7]. Here, CMTM6 is linked to non-small cell lung carcinoma.